[11C]flumazenil metabolite measurement in plasma is not necessary for accurate brain benzodiazepine receptor quantification

被引:15
|
作者
Sanabria-Bohórquez, SM
Labar, D
Levêque, P
Bol, A
De Volder, AG
Michel, C
Veraart, C
机构
[1] Catholic Univ Louvain, Neural Rehabil Engn Lab GREN5446, B-1200 Brussels, Belgium
[2] Catholic Univ Louvain, Positron Emiss Tomog Lab, Brussels, Belgium
[3] Catholic Univ Louvain, Pharmaceut Chem & Radiopharmacol Unit, Brussels, Belgium
关键词
C-11]flumazenil; metabolite correction; simultaneous fitting; benzodiazepine receptors; kinetic modelling;
D O I
10.1007/s002590000336
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In this work, a mathematical correction for metabolites has been validated which estimates the relative amount of [C-11]flumazenil ([C-11]FMZ) in the total plasma curve from the tissue kinetic data without the need for direct metabolite measurement in blood plasma samples. Kinetic data were obtained using a 90-min three-injection protocol on five normal volunteers. First, the relative amount of [C-11]FMZ in plasma was modelled by a two-parameter exponential function. The parameters were estimated either directly by fitting this model to the blood plasma metabolite measurements, or indirectly from the simultaneous fitting of tissue time activity curves from several brain regions with a non-linear FMZ kinetic model. Second, the direct and indirect metabolite corrections were fixed and the FMZ compartmental parameters were determined on a regional basis in the brain. The validation was performed by comparing the regional values of benzodiazepine receptor density B-max and equilibrium dissociation constant K-d Obtained with the direct metabolite correction with those values obtained with the indirect correction. For B-max the correlation coefficient r(2) was above 0.97 for all subjects and the slope values of the linear regression were within the interval [0.97, 1.2]. For K-d, r(2) was above 0.96, and the slope values of the linear regression were within the interval [0.99, 1.1]. Simulation studies were performed in order to evaluate whether this metabolite correction method could be used in a clinical protocol where only a single [C-11]FMZ injection and a linear compartmental model are used. The resulting [C-11]FMZ distribution volume estimates were found to be linearly correlated with the true values, with r(2) = 1.0 and a slope value of 1.1. The mathematical metabolite correction proved to be a feasible and reliable method to estimate the relative amount of [C-11]FMZ in plasma and the compartmental model parameters for time-injection protocols. Although validation with real data is necessary, simulation results suggest that our analysis method may also be applied to single-injection protocols.
引用
收藏
页码:1674 / 1683
页数:10
相关论文
共 50 条
  • [1] [11C]Flumazenil metabolite measurement in plasma is not necessary for accurate brain benzodiazepine receptor quantification
    Sandra M. Sanabria-Bohórquez
    Daniel Labar
    Philippe Levêque
    Anne Bol
    Anne G. De Volder
    Christian Michel
    Claude Veraart
    European Journal of Nuclear Medicine, 2000, 27 : 1674 - 1683
  • [2] Plasma pharmacokinetics of [11C]-flumazenil and its major metabolite [11C]-flumazenil 'acid'
    Franssen, EJF
    Greuter, HNJM
    Touw, DJ
    Luurtsema, G
    Windhorst, AD
    Lammertsma, AA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (05) : 554P - 555P
  • [3] Imaging benzodiazepine receptors in the rat brain using [11C]flumazenil and microPET
    Fryer, TD
    Cleij, MC
    Aigbirhio, FI
    Beech, JS
    Barret, O
    Carpenter, TA
    Menon, DK
    Clark, JC
    Baron, JC
    NEUROIMAGE, 2002, 16 (03) : S26 - S26
  • [4] Comparisons of central benzodiazepine receptor mapping tracers, [18F]Flumazenil and [11C]Flumazenil presentation
    Odano, Ikuo
    Farde, L.
    Savic, I.
    Ciumas, C.
    Krasikova, R.
    Airaksinen, A.
    Karlsson, P.
    Pauli, S.
    Halldin, C.
    NEUROIMAGE, 2006, 31 : T88 - T88
  • [5] Advantage of [18F]flumazenil for central benzodiazepine receptor mapping compared to [11C]flumazenil.
    Odano, I.
    Karlsson, P.
    Farde, L.
    Krasikova, R.
    Airaksinen, A.
    Pauli, S.
    Savic, I.
    Halldin, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S212 - S212
  • [6] Parametric methods for quantification of [11C]Flumazenil studies
    Klumpers, Ursula M. H.
    Boellaard, Ronald
    Veltman, Dick J.
    Kloet, Reina W.
    Hoogendijk, Witte J. G.
    Lammertsma, Adriaan A.
    NEUROIMAGE, 2010, 52 : S189 - S189
  • [7] Use of a standardized uptake value for parametric in vivo imaging of benzodiazepine receptor distribution on [11C]flumazenil brain PET
    Masahito Tsukamoto
    Chietsugu Katoh
    Tohru Shiga
    Tomohito Kaji
    Yuji Kuge
    Kunihiro Nakada
    Nagara Tamaki
    European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 : 846 - 851
  • [8] Use of a standardized uptake value for parametric in vivo imaging of benzodiazepine receptor distribution on [11C]flumazenil brain PET
    Tsukamoto, M
    Katoh, C
    Shiga, T
    Kaji, T
    Kuge, Y
    Nakada, K
    Tamaki, N
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (06) : 846 - 851
  • [9] A new simple automated synthesis of the central benzodiazepine receptor imaging radiotracer [11C]Flumazenil
    Zhang, Zhengwei
    Xue, Fangping
    Du, Fuqiang
    Guan, Yihui
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [10] Quantitative in vivo measurement of central benzodiazepine receptors in the brain of cats by use of positron-emission tomography and [11C]flumazenil
    Shimada, Y
    Kiyosawa, M
    Nariai, T
    Oda, K
    Toyama, H
    Ono, K
    Senda, M
    Ishiwata, K
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2003, 64 (08) : 999 - 1002